SMARCA4 and non-small cell lung carcinoma: When examining class 1 or class 2 mutations regardless of the type of treatment, Fernando et al. compared patients with SMARCA4 WT (N = 2194) vs. SMARCA4 NSCLC mutations in four categories: (a) homozygous truncated (N = 102), (b) homozygous nontruncated (N = 101), (c) heterozygous truncated (N = 16), and (d) heterozygous nontruncated (N = 49] [11].